On October 12, 2023 Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, reported that two abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for poster presentations at the upcoming Congress on October 24-27, 2023, in Brussels, Belgium (Press release, Precision Biosciences, OCT 12, 2023, View Source [SID1234635889]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: Unique features of ARCUS nucleases enable high efficiency, targeted gene insertion in vivo
Poster Number: #P641
Presenter: Cassie Gorsuch, VP of Gene Therapy, Precision Biosciences
Date and Time: Wednesday, October 25, 2023, 5:00 PM – 6:15 PM CEST and Thursday, October 26, 2023, 8:30 PM – 9:30 PM CEST
Location: Gare Maritime

Title: ARCUS-mediated excision of the "hot spot" region of the human dystrophin gene results in functional improvement in a mouse model of Duchenne muscular dystrophy (DMD)
Poster Number: Poster #P653
Presenter: Cassie Gorsuch, VP of Gene Therapy, Precision Biosciences
Date and Time: Wednesday, October 25, 2023, 5:00 PM – 6:15 PM CEST and Thursday, October 26, 2023, 8:30 PM – 9:30 PM CEST
Location: Gare Maritime